Investors Overview
Overview
Alvotech is a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
25
Sep '23
20
Sep '23
11
Sep '23
05
Sep '23
Recent Events
November 14, 2023
September 13, 2023 at 12:15 PM EDT
August 31, 2023 at 8:00 AM EDT